Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BCDA 
Biocardia Inc (BCDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: BCDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.69% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.48M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 1 | Beta 0.66 | 52 Weeks Range 1.00 - 3.20 | Updated Date 12/28/2025 |
52 Weeks Range 1.00 - 3.20 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -86.45% | Return on Equity (TTM) -317.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8829172 | Price to Sales(TTM) 3089.53 |
Enterprise Value 8829172 | Price to Sales(TTM) 3089.53 | ||
Enterprise Value to Revenue 3111.7 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 10612734 | Shares Floating 7207002 |
Shares Outstanding 10612734 | Shares Floating 7207002 | ||
Percent Insiders 27.46 | Percent Institutions 4.03 |
Upturn AI SWOT
Biocardia Inc
Company Overview
History and Background
Cardia Biologics, Inc. was founded in 2000, focusing on regenerative medicine with a core technology for developing autologous cell-based therapies. The company has undergone transformations, including a name change to CardioTherapeutics, Inc. and subsequently to BioCardia, Inc. A significant milestone was the development of its proprietary cell-processing technology aimed at enhancing the efficacy of stem cell therapies for cardiovascular diseases.
Core Business Areas
- Cardiovascular Therapies: Development of autologous cell-based therapies for treating cardiovascular diseases, including heart failure and myocardial infarction. The focus is on leveraging the body's own cells to repair damaged heart tissue.
- Drug Delivery Devices: Development and commercialization of innovative drug delivery devices, including implantable devices designed for controlled release of therapeutic agents directly to the heart.
Leadership and Structure
BioCardia, Inc. is led by a management team with expertise in biotechnology, medical devices, and clinical development. The organizational structure is typical of a clinical-stage biotechnology company, with departments focused on research and development, clinical operations, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- BC-101 (Autologous Cardiomyocyte Progenitor Cells): A cell therapy candidate designed to regenerate damaged heart muscle tissue. It utilizes the patient's own cells, processed and expanded ex vivo. Market share data is not publicly available as it is in clinical development. Competitors include companies developing stem cell therapies and other regenerative medicine approaches for heart failure.
- BC-102 (Autologous Mesenchymal Stem Cells): Another autologous cell therapy candidate targeting cardiovascular diseases. Similar to BC-101, market share data is not applicable at this stage. Competitors include other companies working on MSC-based therapies for various indications.
- CardiaAssist (Ventricular Assist Device): A novel, minimally invasive ventricular assist device (VAD) designed to support patients with advanced heart failure. Specific market share data is not readily available due to its developmental stage and potential niche positioning. Competitors include established VAD manufacturers like Abbott Laboratories and Medtronic.
Market Dynamics
Industry Overview
The biotechnology and medical device industries are characterized by high innovation, significant R&D investment, stringent regulatory processes, and a growing demand for novel treatments for chronic diseases, particularly cardiovascular conditions. The regenerative medicine sector, a key focus for BioCardia, is experiencing rapid advancements and increasing investor interest.
Positioning
BioCardia positions itself as a leader in autologous cell-based therapies for cardiovascular regeneration and in developing advanced cardiac assist devices. Its competitive advantage lies in its proprietary cell processing technology and its focus on personalized medicine.
Total Addressable Market (TAM)
The total addressable market for cardiovascular therapies, including treatments for heart failure and related conditions, is in the tens of billions of dollars globally. BioCardia is positioned to capture a portion of this market with its innovative cell therapies and devices, aiming to address unmet needs in patients who do not respond to existing treatments.
Upturn SWOT Analysis
Strengths
- Proprietary cell processing technology
- Focus on regenerative medicine for cardiovascular diseases
- Development of innovative cardiac assist devices
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- Reliance on significant future funding for R&D and commercialization
- Long development timelines for cell therapies
- Potential manufacturing complexities for autologous therapies
Opportunities
- Growing demand for effective treatments for heart failure
- Advancements in biotechnology and regenerative medicine
- Potential for strategic partnerships and collaborations
- Expansion into other therapeutic areas beyond cardiovascular
Threats
- Regulatory hurdles and lengthy approval processes
- Competition from established pharmaceutical and medical device companies
- Challenges in clinical trial recruitment and success
- Patent expirations and intellectual property challenges
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Medtronic plc (MDT)
- Edwards Lifesciences Corporation (EW)
- Other clinical-stage biotechnology companies developing cell therapies for cardiovascular diseases.
Competitive Landscape
BioCardia faces intense competition from established medical device manufacturers and other biotechnology companies. Its advantages lie in its specialized focus on regenerative cardiovascular therapies and its novel VAD technology. However, it lacks the established market presence, extensive financial resources, and diversified product portfolios of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for BioCardia has been characterized by its evolution from a research-focused entity to a company with multiple product candidates in clinical development. Growth is measured by progress in its pipeline, expansion of its intellectual property, and advancements in its technology platforms.
Future Projections: Future projections for BioCardia are contingent upon the successful completion of its clinical trials, regulatory approvals for its products, and effective commercialization strategies. Analyst estimates, if available, would provide insights into expected future revenue and profitability, but are highly speculative for companies at this stage.
Recent Initiatives: Recent initiatives likely include advancements in ongoing clinical trials for its cell therapy candidates, strategic partnerships to accelerate development, and potentially efforts to secure additional funding to support its pipeline.
Summary
BioCardia Inc. is a clinical-stage biotechnology company with promising regenerative medicine therapies for cardiovascular diseases and innovative cardiac assist devices. Its strengths lie in its proprietary technology and focused pipeline. However, it faces significant challenges due to its lack of approved products, reliance on funding, and the highly competitive landscape. Success hinges on positive clinical trial outcomes and regulatory approvals, alongside effective market penetration strategies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Company Investor Relations
- Industry research reports
- Financial data providers (e.g., Yahoo Finance, Bloomberg - where general market data is accessed)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data for clinical-stage companies is often estimated or not directly comparable to established players.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biocardia Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2008-03-14 | CEO, President & Director Dr. Peter A. Altman Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.biocardia.com |
Full time employees 17 | Website https://www.biocardia.com | ||
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.